Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Salgado

Showing results (191-200 of 277) with videos related to

Pageof 28
Sort By:
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
JCO Precision Oncology|September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple CancersScooter Willis, Yuliang Sun, Mark Abramovitz, et al.
NPJ Breast Cancer|January 12, 2022
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancerSherene Loi, Roberto Salgado, Sylvia Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2019
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast CancersSherene Loi, Damien Drubay, Sylvia Adams, et al.
Histopathology|March 3, 2024
Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific researchAmy Ly, Victor Garcia, Kim R M Blenman, et al.
Journal of Pathology Informatics|December 9, 2021
A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot StudySarah N Dudgeon, Si Wen, Matthew G Hanna, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
NPJ Digital Medicine|March 5, 2026
Clarifying validation terminologies in healthcareAmanda Dy, Sandra M Buetow, Andrew J Bredemeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast CancerMarleen Kok, Robbert-Jan Gielen, Sylvia Adams, et al.
Nature Medicine|June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trialAlex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
Pageof 28

Showing results (191-200 of 277) with videos related to

Sort By:
Pageof 28
JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.
JCO Precision Oncology|September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple CancersScooter Willis, Yuliang Sun, Mark Abramovitz, et al.
NPJ Breast Cancer|January 12, 2022
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancerSherene Loi, Roberto Salgado, Sylvia Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2019
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast CancersSherene Loi, Damien Drubay, Sylvia Adams, et al.
Histopathology|March 3, 2024
Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific researchAmy Ly, Victor Garcia, Kim R M Blenman, et al.
Journal of Pathology Informatics|December 9, 2021
A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot StudySarah N Dudgeon, Si Wen, Matthew G Hanna, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
NPJ Digital Medicine|March 5, 2026
Clarifying validation terminologies in healthcareAmanda Dy, Sandra M Buetow, Andrew J Bredemeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast CancerMarleen Kok, Robbert-Jan Gielen, Sylvia Adams, et al.
Nature Medicine|June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trialAlex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
Pageof 28